BidaskClub cut shares of Athenex (NASDAQ:ATNX) from a strong-buy rating to a buy rating in a research note issued to investors on Thursday.
Several other analysts have also issued reports on ATNX. Zacks Investment Research raised Athenex from a hold rating to a buy rating and set a $19.00 target price on the stock in a report on Tuesday, April 10th. Needham & Company LLC assumed coverage on Athenex in a report on Tuesday, March 6th. They set a buy rating and a $30.00 target price on the stock. JPMorgan Chase increased their target price on Athenex from $22.20 to $23.00 and gave the stock a neutral rating in a report on Wednesday, January 24th. Finally, Deutsche Bank set a $20.00 target price on Athenex and gave the stock a buy rating in a report on Wednesday, January 17th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Athenex currently has an average rating of Buy and a consensus target price of $26.86.
ATNX opened at $16.30 on Thursday. The firm has a market cap of $1,055.88 and a PE ratio of -7.03. Athenex has a 52-week low of $11.21 and a 52-week high of $20.79. The company has a current ratio of 1.86, a quick ratio of 1.49 and a debt-to-equity ratio of 0.01.
Athenex (NASDAQ:ATNX) last released its earnings results on Monday, March 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.33). The firm had revenue of $14.87 million during the quarter. equities analysts forecast that Athenex will post -1.4 earnings per share for the current year.
In other Athenex news, CEO Johnson Yiu Nam Lau acquired 20,000 shares of Athenex stock in a transaction that occurred on Thursday, February 8th. The shares were acquired at an average cost of $14.40 per share, with a total value of $288,000.00. Following the completion of the purchase, the chief executive officer now directly owns 2,767,922 shares of the company’s stock, valued at approximately $39,858,076.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Manson Fok acquired 30,000 shares of Athenex stock in a transaction that occurred on Wednesday, February 7th. The stock was acquired at an average cost of $14.31 per share, for a total transaction of $429,300.00. Following the completion of the purchase, the director now directly owns 1,799,609 shares of the company’s stock, valued at $25,752,404.79. The disclosure for this purchase can be found here. Insiders purchased 89,500 shares of company stock worth $1,287,550 over the last ninety days.
Large investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC acquired a new stake in Athenex in the fourth quarter valued at about $161,000. California State Teachers Retirement System acquired a new stake in Athenex in the third quarter valued at about $198,000. Deutsche Bank AG boosted its stake in Athenex by 190.8% in the fourth quarter. Deutsche Bank AG now owns 18,511 shares of the company’s stock valued at $293,000 after buying an additional 12,146 shares in the last quarter. Virtus Fund Advisers LLC bought a new position in Athenex in the fourth quarter valued at about $333,000. Finally, Schwab Charles Investment Management Inc. bought a new position in Athenex in the third quarter valued at about $524,000. 5.86% of the stock is currently owned by institutional investors and hedge funds.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. Its Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.